Predictors of cognitive dysfunction in hereditary transthyretin amyloidosis with liver transplant
Sara Cavaco(Centro Hospitalar do Porto), Teresa Coelho(Universidade do Porto), Joana Fernandes(Universidade do Porto), Cristina Alves(Centro Hospitalar do Porto), Ana Silva(Alnylam Pharmaceuticals (United States)), Ana Paula Sousa(Centro Hospitalar Lisboa Norte), Márcio Cardoso(Centro Hospitalar Lisboa Norte), Armando Teixeira‐Pinto(The University of Sydney)
Cited by 7
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis
|New England Journal of Medicine|2013|961
Multiple Sclerosis Severity Score
|Neurology|2005|959
Genotype and Phenotype of Transthyretin Cardiac Amyloidosis
|Journal of the American College of Cardiology|2016|540